Previous 10 | Next 10 |
ADMA Biologics (NASDAQ: ADMA ) is up 10% premarket on announcing preliminary Q4 and FY 2019 revenues, providing updates on the commercial launches of BIVIGAM and ASCENIV, as well as introducing 2020 strategic outlook. More news on: ADMA Biologics, Inc., Healthcare stocks news...
Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018 Full Year 2019 Preliminary Unaudited Total Revenues of $29.2 Million, a 72% Increase Over Full Year 2018 ADMA to Host Conference Call and Webcast in the Firs...
Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA), a commercial biopharmaceutical company dedicated t...
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for ...
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for ...
Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA RATON, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (ADMA or the Company), a c...
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 04, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for ...
ADMA Biologics (ADMA) recently announced their first commercial sales of ASCENIV. Accordingly, the market embraced the announcement, and the share price spiked up to just under $5.00 per share. Although the first sale of a product is not a marquis catalyst for most biotech companies, ASCENIV...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for ...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...